Literature DB >> 2285636

Stability of plasma amiodarone levels during chronic oral therapy.

K Robinson1, A Johnston, S Walker, J Mulrow, D Holt, W McKenna.   

Abstract

The variability of plasma amiodarone levels in 51 patients receiving chronic oral therapy over 4-53 (median 19) months was examined; 3-14 (median 5) plasma samples were obtained. After a loading dose, most patients received either 200 mg or 400 mg a day. Mean plasma amiodarone concentration was 1.2 +/- 0.6 mg/l and mean plasma desethylamiodarone concentration was 1.2 +/- 0.5 mg/l. No relationship was seen between height and weight and plasma concentrations. Dose was a significant predictor of plasma level (p less than 0.01) although it was a poor predictor of steady state amiodarone concentration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2285636     DOI: 10.1007/bf01857765

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  7 in total

1.  Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.

Authors:  M Stäubli; J Bircher; R L Galeazzi; H Remund; H Studer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Prolongation of verapamil elimination kinetics during chronic oral administration.

Authors:  J B Schwartz; D L Keefe; E Kirsten; R E Kates; D C Harrison
Journal:  Am Heart J       Date:  1982-08       Impact factor: 4.749

3.  High-performance liquid chromatographic measurement of amiodarone and desethylamiodarone in plasma or serum at the concentrations attained following a single 400-mg dose.

Authors:  G C Storey; D W Holt
Journal:  J Chromatogr       Date:  1982-08-27

4.  Influence of long-term infusions on lidocaine kinetics.

Authors:  L A Bauer; T Brown; M Gibaldi; L Hudson; S Nelson; V Raisys; J P Shea
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

5.  Relationships between amiodarone dosage, drug concentrations, and adverse side effects.

Authors:  J J Heger; E N Prystowsky; D P Zipes
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

6.  Amiodarone pharmacokinetics.

Authors:  D W Holt; G T Tucker; P R Jackson; G C Storey
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

7.  Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias.

Authors:  C I Haffajee; J C Love; A T Canada; L J Lesko; G Asdourian; J S Alpert
Journal:  Circulation       Date:  1983-06       Impact factor: 29.690

  7 in total
  1 in total

Review 1.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.